<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00946088</url>
  </required_header>
  <id_info>
    <org_study_id>SU-03312009-2078</org_study_id>
    <secondary_id>11625</secondary_id>
    <nct_id>NCT00946088</nct_id>
  </id_info>
  <brief_title>Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial</brief_title>
  <official_title>Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm delivery is the most common cause of infant morbidity and mortality in the United
      States. Some women have episodes of preterm labor during their pregnancy which can be
      temporarily stopped. These women, however, are at high risk for delivering before term. At
      this time, we do not have sufficient evidence to use any medication to help prevent these
      women from delivering early. Recently, preliminary studies have shown that progesterone may
      help prevent some women at high risk for preterm delivery from delivering early. Our study
      will investigate whether progesterone can help this specific group of women, women with
      arrested preterm labor, deliver healthy infants at term.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to test the efficacy of progesterone in prolonging human
      pregnancies complicated by arrested preterm labor. Animal labor has not been shown to be
      equivalent to human labor and would not be an appropriate substitute for this study.

      In addition, this medication has been previously used in pregnant women without any evidence
      of significant harm to the mother or fetus. Women will be approached for enrollment in the
      study during their hospitalization for preterm labor. If they choose to enroll, they will
      have weekly MD visits at the obstetrical clinic, daily use of vaginal progesterone that will
      be self administered, and routine obstetric care at the time of recurrent labor and delivery.
      The daily progesterone is not a part of routine care for these patients. In addition, we will
      ask patients to fill out a written questionaire one week after starting the medication to
      describe any subjective symptoms that may be associated with this medication. Finally, we
      will assess the peripheral levels of progesterone with a blood draw prior to starting the
      mediation, one week after starting the medication, and at the time of recurrent pre-term
      labor or delivery. The first two of these blood draws will be in addition to the standard
      treatment. The final blood draw will involve collecting an extra sample at a time when the
      participant would normally have blood drawn as a part of routine care.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lower than expected enrollment
  </why_stopped>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Delivery Rate Prior to 37 Weeks Gestation</measure>
    <time_frame>Up to 37 weeks of gestation</time_frame>
    <description>Reduction in delivery rate prior to 37 weeks gestation (preterm birth).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal Chorioamnionitis</measure>
    <time_frame>Up to maternal hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Anticipated Adverse Medication Reaction</measure>
    <time_frame>Up to the maternal discharge from delivery hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birthweight</measure>
    <time_frame>At the time of newborn birth</time_frame>
    <description>Newborn birthweight in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Intensive Care Unit (NICU) Admission</measure>
    <time_frame>At time of neonatal discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Morbidity</measure>
    <time_frame>Up to 28 days after neonatal birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Mortality</measure>
    <time_frame>Up to 28 days after neonatal birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Congenital Abnormalities</measure>
    <time_frame>Up to the time of neonatal discharge from the delivery hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Delay of Delivery</measure>
    <time_frame>Up to the time of delivery</time_frame>
    <description>Number of days from intervention to delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Pregnancy Complications</condition>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Progesterone 400mg per vagina qhs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polyethylene glycol&amp;hydrogenated vegetable oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Polyethylene glycol&amp;hydrogenated vegetable oil per vagina</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Progesterone 400 mg per vagina qhs.</description>
    <arm_group_label>Progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene glycol&amp;hydrogenated vegetable oil.</intervention_name>
    <description>Placebo Comparator: Polyethylene glycol 400 distearate &amp; hydrogenated vegetable oil per vagina qhs.</description>
    <arm_group_label>Polyethylene glycol&amp;hydrogenated vegetable oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:1. Pregnant women with arrested preterm labor between 24+0 to 33+6 weeks
        pregnant.

        2. Intact membranes 3. Singleton pregnancy 4. Greater than or equal to 18 years of age 5.
        Cervical dilation less than or equal to 4cm

        Exclusion Criteria:1. Any contraindication to on-going pregnancy 2. Placental abruption 3.
        Placenta previa 4. Lethal fetal anomalies 5. Premature rupture of membranes 6. Multiple
        gestation 7. Less than 18 years old 8. Known allergy to any component of the study
        medication or placebo 9. Severe maternal medical illness
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deirdre Judith Lyell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <results_first_submitted>October 24, 2016</results_first_submitted>
  <results_first_submitted_qc>December 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2017</results_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Deirdre Judith Lyell</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled from November 2010 through February 2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Progesterone</title>
          <description>Progesterone 400 mg per vagina qhs.</description>
        </group>
        <group group_id="P2">
          <title>Polyethylene Glycol 400 Distearate &amp; Hydrogenated Vegetable oi</title>
          <description>Polyethylene glycol 400 distearate &amp; hydrogenated vegetable oil</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4">At least one dose administered and pre-term birth status known.</participants>
                <participants group_id="P2" count="2">At least one dose administered and pre-term birth status known.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Progesterone</title>
          <description>Progesterone 400 mg per vagina qhs.</description>
        </group>
        <group group_id="B2">
          <title>Polyethylene Glycol &amp; Hydrogenated Vegetable Oil</title>
          <description>Polyethylene glycol 400 distearate &amp; hydrogenated vegetable oil</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.5" lower_limit="24" upper_limit="33"/>
                    <measurement group_id="B2" value="27.0" lower_limit="19" upper_limit="34"/>
                    <measurement group_id="B3" value="27.9" lower_limit="19" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Delivery Rate Prior to 37 Weeks Gestation</title>
        <description>Reduction in delivery rate prior to 37 weeks gestation (preterm birth).</description>
        <time_frame>Up to 37 weeks of gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Progesterone 400 mg per vagina qhs.</description>
          </group>
          <group group_id="O2">
            <title>Polyethylene Glycol&amp;Hydrogenated Vegetable Oil</title>
            <description>Polyethylene glycol 400 distearate &amp; hydrogenated vegetable oil per vagina</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Delivery Rate Prior to 37 Weeks Gestation</title>
          <description>Reduction in delivery rate prior to 37 weeks gestation (preterm birth).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Delivery at &lt;37 weeks of gestation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delivery at &gt;=37 weeks of gestation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Chorioamnionitis</title>
        <time_frame>Up to maternal hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Progesterone 400 mg per vagina qhs.</description>
          </group>
          <group group_id="O2">
            <title>Polyethylene Glycol &amp; Hydrogenated Vegetable Oil</title>
            <description>Polyethylene glycol 400 distearate &amp; hydrogenated vegetable oil per vagina</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Chorioamnionitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Anticipated Adverse Medication Reaction</title>
        <time_frame>Up to the maternal discharge from delivery hospitalization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Progesterone 400 mg per vagina qhs.</description>
          </group>
          <group group_id="O2">
            <title>Polyethylene &amp; Hydrogenated Vegetable Oil</title>
            <description>Polyethylene glycol 400 distearate &amp; hydrogenated vegetable oil per vagina</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Anticipated Adverse Medication Reaction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Birthweight</title>
        <description>Newborn birthweight in grams</description>
        <time_frame>At the time of newborn birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Progesterone 400 mg per vagina qhs.</description>
          </group>
          <group group_id="O2">
            <title>Polyethylene Glycol &amp; Hydrogenated Vegetable Oil</title>
            <description>Polyethylene glycol 400 distearate &amp; hydrogenated vegetable oil per vagina</description>
          </group>
        </group_list>
        <measure>
          <title>Birthweight</title>
          <description>Newborn birthweight in grams</description>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2740" lower_limit="1390" upper_limit="3720"/>
                    <measurement group_id="O2" value="3275" lower_limit="3070" upper_limit="3380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Intensive Care Unit (NICU) Admission</title>
        <time_frame>At time of neonatal discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Progesterone 400 mg per vagina qhs.</description>
          </group>
          <group group_id="O2">
            <title>Polyethylene Glycol &amp; Hydrogenated Vegetable Oil</title>
            <description>Polyethylene glycol 400 distearate &amp; hydrogenated vegetable oil per vagina</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Intensive Care Unit (NICU) Admission</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Morbidity</title>
        <time_frame>Up to 28 days after neonatal birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Progesterone 400 mg per vagina qhs.</description>
          </group>
          <group group_id="O2">
            <title>Polyethylene Glycol &amp; Hydrogenated Vegetable Oil</title>
            <description>Polyethylene glycol 400 distearate &amp; hydrogenated vegetable oil per vagina</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Morbidity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Mortality</title>
        <time_frame>Up to 28 days after neonatal birth</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Progesterone 400 mg per vagina qhs.</description>
          </group>
          <group group_id="O2">
            <title>Polyethylene Glycol &amp; Hydrogenated Vegetable Oil</title>
            <description>Polyethylene glycol 400 distearate &amp; hydrogenated vegetable oil per vagina</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Congenital Abnormalities</title>
        <time_frame>Up to the time of neonatal discharge from the delivery hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Progesterone 400 mg per vagina qhs.</description>
          </group>
          <group group_id="O2">
            <title>Polyethylene Glycol &amp; Hydrogenated Vegetable Oil</title>
            <description>Polyethylene glycol 400 distearate &amp; hydrogenated vegetable oil per vagina</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Congenital Abnormalities</title>
          <units>Neonates</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Delay of Delivery</title>
        <description>Number of days from intervention to delivery</description>
        <time_frame>Up to the time of delivery</time_frame>
        <population>exact delivery data unavailable for one term participant</population>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Progesterone 400 mg per vagina qhs.</description>
          </group>
          <group group_id="O2">
            <title>Polyethylene Glycol &amp; Hydrogenated Vegetable Oil</title>
            <description>Polyethylene glycol 400 distearate &amp; hydrogenated vegetable oil per vagina</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Delay of Delivery</title>
          <description>Number of days from intervention to delivery</description>
          <population>exact delivery data unavailable for one term participant</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0" lower_limit="6" upper_limit="62"/>
                    <measurement group_id="O2" value="47.5" lower_limit="43" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 28 days after the delivery.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Comparator: Progesterone</title>
          <description>Progesterone 400mg per vagina qhs.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Comparator: Polyethylene Glycol&amp;Hydrogenated Vegetab</title>
          <description>Placebo Comparator:Polyethylene glycol&amp;hydrogenated vegetable oil per vagina.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Very limited enrollment, study terminated early.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Deirdre Lyell, MD</name_or_title>
      <organization>Stanford University School of Medicine</organization>
      <phone>(650) 384-5107</phone>
      <email>deirdre.lyell@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

